1
|
Bjornard K, Close A, Burns K, Chavez J, Chow EJ, Meacham LR. Fertility preservation in pediatric solid tumors: A report from the Children's Oncology Group. Pediatr Blood Cancer 2024; 71:e30960. [PMID: 38532279 DOI: 10.1002/pbc.30960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2023] [Revised: 01/30/2024] [Accepted: 02/27/2024] [Indexed: 03/28/2024]
Abstract
Treatment for childhood solid tumors may lead to an increased risk for gonadal dysfunction/infertility. Discussion of risk should occur at diagnosis, any changes in therapy, and during survivorship. Gonadotoxic therapies were abstracted from 32 Children's Oncology Group (COG) phase III, frontline solid tumor protocols, in use from 2000 to 2022. Risk for gonadal dysfunction/infertility was assessed based on gonadotoxic therapies, sex, and pubertal status and assigned as minimal, significant, and high following the Oncofertility Consortium Pediatric Initiative Network (PIN) risk stratification. Most protocols (65.6%, 21/32) contained at least one therapeutic arm with a high level of increased risk. Solid tumor therapies present challenges in risk stratification due to response-adjusted therapy and the need to account for radiation field in the risk assessment. This guide hopes to serve as a tool to assist in standardizing gonadotoxic risk assessments across disciplines and improve referral for fertility services and reproductive health counseling for patients receiving COG-based solid tumor therapy. Internationally, many solid tumor therapies follow similar paradigms to COG studies, and risk stratifications may be generalizable to similar styles of therapy. In addition, this model may be applied to other international groups with the goal of standardizing fertility assessments.
Collapse
Affiliation(s)
- Kari Bjornard
- Department of Pediatrics, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Indiana, USA
- Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, USA
| | - Allison Close
- Division of Hematology/Oncology, Helen DeVos Children's Hospital, Michigan State University College of Human Medicine, Grand Rapids, Michigan, USA
| | - Karen Burns
- Department of Pediatrics, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Cincinnati, Ohio, USA
| | - Josuah Chavez
- Division of Hematology/Oncology, Helen DeVos Children's Hospital, Grand Rapids, Michigan, USA
| | - Eric J Chow
- Fred Hutchinson Cancer Center, Seattle Children's Hospital, Seattle, Washington, USA
| | - Lillian R Meacham
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Pediatric Hematology/Oncology/BMT, Emory University Atlanta, Atlanta, Georgia, USA
| |
Collapse
|
2
|
Quintanilla J, Jia Y, Pruess BS, Chavez J, Gall CM, Lynch G, Gunn BG. Pre- versus Post-synaptic Forms of LTP in Two Branches of the Same Hippocampal Afferent. J Neurosci 2024; 44:e1449232024. [PMID: 38326038 PMCID: PMC10919254 DOI: 10.1523/jneurosci.1449-23.2024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Revised: 12/18/2023] [Accepted: 01/22/2024] [Indexed: 02/09/2024] Open
Abstract
There has been considerable controversy about pre- versus postsynaptic expression of memory-related long-term potentiation (LTP), with corresponding disputes about underlying mechanisms. We report here an instance in male mice, in which both types of potentiation are expressed but in separate branches of the same hippocampal afferent. Induction of LTP in the dentate gyrus (DG) branch of the lateral perforant path (LPP) reduces paired-pulse facilitation, is blocked by antagonism of cannabinoid receptor type 1, and is not affected by suppression of postsynaptic actin polymerization. These observations are consistent with presynaptic expression. The opposite pattern of results was obtained in the LPP branch that innervates the distal dendrites of CA3: LTP did not reduce paired-pulse facilitation, was unaffected by the cannabinoid receptor blocker, and required postsynaptic actin filament assembly. Differences in the two LPP termination sites were also noted for frequency facilitation of synaptic responses, an effect that was reproduced in a two-step simulation by small adjustments to vesicle release dynamics. These results indicate that different types of glutamatergic neurons impose different forms of filtering and synaptic plasticity on their afferents. They also suggest that inputs are routed to, and encoded by, different sites within the hippocampus depending upon the pattern of activity arriving over the parent axon.
Collapse
Affiliation(s)
- J Quintanilla
- Department of Anatomy & Neurobiology, University of California, Irvine, California 92697
| | - Y Jia
- Department of Anatomy & Neurobiology, University of California, Irvine, California 92697
| | - B S Pruess
- Department of Anatomy & Neurobiology, University of California, Irvine, California 92697
| | - J Chavez
- Department of Anatomy & Neurobiology, University of California, Irvine, California 92697
| | - C M Gall
- Department of Anatomy & Neurobiology, University of California, Irvine, California 92697
- Neurobiology & Behavior, University of California, Irvine, California 92697
| | - G Lynch
- Department of Anatomy & Neurobiology, University of California, Irvine, California 92697
- Psychiatry & Human Behavior, University of California, Irvine, California 92697
| | - B G Gunn
- Department of Anatomy & Neurobiology, University of California, Irvine, California 92697
| |
Collapse
|
3
|
Close A, Burns K, Bjornard K, Webb M, Chavez J, Chow EJ, Meacham L. Fertility preservation in pediatric leukemia and lymphoma: A report from the Children's Oncology Group. Pediatr Blood Cancer 2023; 70:e30407. [PMID: 37194406 PMCID: PMC10525075 DOI: 10.1002/pbc.30407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/19/2023] [Revised: 04/13/2023] [Accepted: 04/17/2023] [Indexed: 05/18/2023]
Abstract
Certain chemotherapy agents, radiation, and surgery can all negatively impact future fertility. Consults regarding treatment-related risk for infertility and gonadal late effects of these agents should occur at the time of diagnosis as well as during survivorship. Counseling on fertility risk has traditionally varied significantly across providers and institutions. We aim to provide a guide to standardize the assignment of gonadotoxic risk, which can be used in counseling patients both at the time of diagnosis and in survivorship. Gonadotoxic therapies were abstracted from 26 frontline Children's Oncology Group (COG) phase III protocols for leukemia/lymphoma, in use from 2000-2022. A stratification system based on gonadotoxic therapies, sex, and pubertal status was used to assign treatments into minimal, significant, and high level of increased risk for gonadal dysfunction/infertility. Risk levels were assigned to protocols and different treatment arms to aid oncologists and survivor care providers in counseling patients regarding treatment-related gonadotoxicity. Males were most commonly at high risk, with at least one high-risk arm in 14/26 protocols (54%), followed by pubertal females (23% of protocols) and prepubertal females (15% of protocols). All patients who received direct gonadal radiation or hematopoietic stem cell transplant (HSCT) were considered at high risk. Partnering with patients and their oncology/survivorship team is imperative for effective fertility counseling both prior to and post treatment, and this comprehensive guide can be used as a tool to standardize and improve reproductive health counseling in patients undergoing COG-based leukemia/lymphoma care.
Collapse
Affiliation(s)
- Allison Close
- Helen DeVos Children’s Hospital, Division of Hematology/Oncology, Michigan State University College of Human Medicine, Grand Rapids, MI, USA
| | - Karen Burns
- Cancer and Blood Diseases Institute, Cincinnati Children’s Hospital Medical Center, Department of Pediatrics, University of Cincinnati School of Medicine, Cincinnati, OH, USA
| | - Kari Bjornard
- Department of Pediatrics, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IN, USA; Riley Hospital for Children at Indiana University Health, Indianapolis, IN, USA
| | - Martine Webb
- University of California, Los Angeles, Division of Internal Medicine, Los Angeles, CA, USA
| | - Josuah Chavez
- Helen DeVos Children’s Hospital, Division of Hematology/Oncology, Grand Rapids, MI, USA
| | - Eric J. Chow
- Fred Hutchinson Cancer Center, Seattle Children’s Hospital, Seattle, WA, USA
| | - Lillian Meacham
- Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Pediatric Hematology/Oncology/BMT, Emory University Atlanta, GA USA
| |
Collapse
|
4
|
Figura N, Sim A, Dahiya S, Lutfi F, Rapoport A, Mohindra P, Dohm A, Chavez J, Shah B, Khimani F, Lazaryan A, Davila M, Bachmeier C, Nishihori T, Liu H, Kim S, Locke F, Jain M, Robinson T. PO-1075 Bridging Radiotherapy prior to Brexucabtagene Autoleucel CAR T-Cell Therapy in Mantle Cell Lymphoma. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07526-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
5
|
Karmali R, Donovan A, Wagner‐Johntson N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Ristow K, Lansigan F, Kaplan JB, Caimi PB, Rajguru S, Evens A, Klein A, Umyarova E, Amengual JE, Lue JK, Diefenbach C, Epperla N, Barta SK, Hernandez‐Ilizaliturri FJ, Handorf E, Villa D, Gerrie AS, Li S, Mederios J, Wang M, Cohen J, Calzada O, Churnetski M, Hill B, Sawalha Y, Gerson JN, Kothari S, Vose JM, Bast M, Fenske TS, Narayana Rao Gari S, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B. SURVIVAL FOLLOWING FIRST RELAPSE IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.60_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
| | - A. Donovan
- Dartmouth Hitchcock, Hem Onc Lebanon USA
| | | | - M. Messmer
- Johns Hopkins University, Hem Onc Baltimore USA
| | - A. Mehta
- University of Alabama Cancer Center, Hem Onc Birmingham USA
| | - J. K. Anderson
- University of Alabama Cancer Center, Hem Onc Birmingham USA
| | - N. Reddy
- Vanderbilt Ingram Cancer Center, Hem Onc Nashville USA
| | - A. E. Kovach
- Vanderbilt Ingram Cancer Center, Hem Onc Nashville USA
| | - D. J. Landsburg
- University of Pennsylvania, Hematology Oncology Philadelphia Pennsylvania USA
| | - M. Glenn
- Huntsman Cancer Institute, Hem Onc Salt Lake City USA
| | | | | | | | | | - P. B. Caimi
- Case Western Reserve University, Hem Onc Cleveland USA
| | - S. Rajguru
- University of Wisconsin, Hem Onc Madison USA
| | - A. Evens
- Rutgers, Hem Onc New Brunswick USA
| | | | - E. Umyarova
- University of Vermont, Hem Onc Burlington USA
| | | | | | | | - N. Epperla
- Ohio State University, Hem Onc Columbus USA
| | - S. K. Barta
- University of Pennsylvania, Hematology Oncology Philadelphia Pennsylvania USA
| | | | - E. Handorf
- Fox Chase Cancer Center, Hematology Oncology Philadelphia USA
| | - D. Villa
- BC Cancer, Hem Onc Vancouver Canada
| | | | - S. Li
- MD Anderson, Hem Onc Houstin USA
| | | | - M. Wang
- MD Anderson, Hem Onc Houstin USA
| | | | | | | | | | | | - J. N. Gerson
- University of Pennsylvania, Hematology Oncology Philadelphia Pennsylvania USA
| | | | - J. M. Vose
- University of Nebraska Cancer Center, Hem Onc Omaha USA
| | - M. Bast
- University of Nebraska Cancer Center, Hem Onc Omaha USA
| | - T. S. Fenske
- Medical College of Wisconsin, Hem Onc Milwaukee USA
| | | | | | - D. Bond
- Ohio State University, Hem Onc Columbus USA
| | - V. Bachanova
- University of Minnesota , Hem Onc Minneapolis USA
| | - B. Kolla
- University of Minnesota , Hem Onc Minneapolis USA
| | - J. Chavez
- Moffitt Cancer Center, Hem Onc Tampa USA
| | - B. Shah
- Moffitt Cancer Center, Hem Onc Tampa USA
| |
Collapse
|
6
|
Diefenbach C, Budde E, Chavez J, Lossos IS, Mehta A, Dorritie K, Kamdar M, Negricea R, Pham S, Hristopoulos M, Huw LY, Hear CO, Oki Y, To I, Ghosh N. PROMISING CLINICAL DATA FROM DOSE ESCALATION IN A PHASE IB/II ONGOING STUDY OF MOSUNETUZUMAB WITH POLATUZUMAB VEDOTIN FOR RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN’S LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.154_2880] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- C Diefenbach
- Perlmutter Cancer Center at NYU Langone Health Division of Hematology and Medical Oncology New York USA
| | - E Budde
- City of Hope National Medical Center Hematology & Hematopoietic Cell Transplantation Duarte California USA
| | - J Chavez
- Moffitt Cancer Center Malignant Hematology Tampa USA
| | - I. S Lossos
- Sylvester Comprehensive Cancer Center University of Miami Health System Division of Hematology Miami USA
| | - A Mehta
- O’Neal Comprehensive Cancer Center at The University of Alabama at Birmingham Division of Hematology and Oncology Birmingham USA
| | - K Dorritie
- UPMC Hillman Cancer Center Division of Hematology/Oncology Pittsburgh USA
| | - M Kamdar
- University of Colorado Cancer Center Medicine‐Hematology Aurora Colorado USA
| | - R Negricea
- F. Hoffmann‐La Roche Ltd Product Development ‐ Clinical Safety Basel Switzerland
| | - S Pham
- F. Hoffmann‐La Roche Ltd Product Development ‐ Biometrics Biostatistics Mississauga Canada
| | - M Hristopoulos
- Genentech, Inc. In Vivo Pharmacology South San Francisco USA
| | - Ling-Y Huw
- Genentech, Inc. Department of Oncology Biomarker Development South San Francisco USA
| | - C. O Hear
- Genentech, Inc. Product Development Hematology South San Francisco USA
| | - Y Oki
- Genentech, Inc. Product Development Oncology South San Francisco USA
| | - I To
- Genentech, Inc. Product Development Clinical Science South San Francisco USA
| | - N Ghosh
- Levine Cancer Institute/Atrium Health Hematologic Oncology and Blood Disorders Charlotte USA
| |
Collapse
|
7
|
Michot J, Carpio C, Nastoupil L, Chavez J, Feldman T, Ferrari S, Morillo D, Bachy E, Pinto A, Kuruvilla J, Buchholz TJ, Kasibhatla S, Carrancio S, Guarinos C, Wu F, Li S, Patah P, Pourdehnad M. A PHASE 1, MULTICENTER, OPEN‐LABEL STUDY OF CC‐99282 ALONE AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMAS. Hematol Oncol 2021. [DOI: 10.1002/hon.89_2881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- J.‐M. Michot
- Gustave Roussy Institute of Cancer Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP) Villejuif France
| | - C. Carpio
- Vall d'Hebron Institute of Oncology (VHIO) University Hospital Vall d'Hebron University Autònoma of Barcelona (UAB) Department of Hematology Barcelona Spain
| | - L. Nastoupil
- MD Anderson Cancer Center University of Texas Department of Lymphoma & Myeloma Houston Texas USA
| | - J. Chavez
- Moffitt Cancer Center University of South Florida Department of Malignant Hematology Tampa Florida USA
| | - T. Feldman
- Hackensack Meridian Health Lymphoma Division Edison New Jersey USA
| | - S. Ferrari
- Papa Giovanni XXIII Hospital Dipartimento di Ematologia Bergamo Italy
| | - D. Morillo
- Hospital Fundación Jiménez Díaz Department of Hematology Madrid Spain
| | - E. Bachy
- Hospices Civils de Lyon Department of Hematology Lyon France
| | - A. Pinto
- National Cancer Institute Fondazione G. Pascale IRCCS Hematology‐Oncology & Stem Cell Transplantation Unit Napoli Italy
| | - J. Kuruvilla
- Princess Margaret Cancer Centre Cancer Clinical Research Unit Division of Medical Oncology and Hematology Toronto Canada
| | - T. J. Buchholz
- Bristol Myers Squibb Early Clinical Development Oncology Princeton New Jersey USA
| | - S. Kasibhatla
- Bristol Myers Squibb Translational Biology Oncogenesis Therapeutic Research Center Princeton New Jersey USA
| | - S. Carrancio
- Bristol Myers Squibb Translational Biology Oncogenesis Therapeutic Research Center Princeton New Jersey USA
| | - C. Guarinos
- Bristol Myers Squibb ONC‐TRC CITRE Princeton New Jersey USA
| | - F. Wu
- Bristol Myers Squibb Clinical Pharmacology Early Clinical Development Princeton New Jersey USA
| | - S. Li
- Bristol Myers Squibb Global Biometric Sciences Princeton New Jersey USA
| | - P. Patah
- Bristol Myers Squibb Early Clinical Development Hematology/Oncology and Cell Therapy Princeton New Jersey USA
| | - M. Pourdehnad
- Bristol Myers Squibb Early Clinical Development Hematology/Oncology and Cell Therapy Princeton New Jersey USA
| |
Collapse
|
8
|
Gryczynski Z, Kimball J, Fudala R, Chavez J, Ceresa L, Szabelski M, Borejdo J, Gryczynski I. Photophysical properties of 2-Phenylindole in poly (vinyl alcohol) film at room temperature. Enhanced phosphorescence anisotropy with direct triplet state excitation. Methods Appl Fluoresc 2020; 8:014008. [PMID: 31851960 DOI: 10.1088/2050-6120/ab6366] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
We report the spectral properties of 2-Phenylindole (2PI) embedded in rigid poly (vinyl alcohol) (PVA) film. The 2PI in PVA film shows relatively strong and structured fluorescence with a maximum at 370 nm and surprisingly strong room temperature phosphorescence with an emission maximum of about 500 nm. The dye is highly immobilized in the polymer matrix, thus presenting high fluorescence anisotropy in an isotropic film of about 0.3 at room temperature. The 2-Phenylindole phosphorescence excited in the usual way through the electronic singlet state excitation (S0 → S1 absorption) results in a very low, near zero anisotropy. We now report that we can directly excite the dye to the triplet state T1 and observe high phosphorescence anisotropy similar to the fluorescence anisotropy. The extinction coefficient for S0 → T1 absorption in the PVA matrix is unusually high- only about 3 orders of magnitude lower than S0 → S1 absorption. We consider this direct excitation to indole's triplet state a very significant finding that may lead to many practical applications. The unusually long-wavelength of excitation around 400 nm, much above typical UV absorption, results in a high phosphorescence anisotropy. This provides a new way to study rotational motion of larger biological objects in the microsecond time scale not accessible through typical fluorescence studies.
Collapse
Affiliation(s)
- Z Gryczynski
- Department of Microbiology, Immunology and Genetics, Center for Fluorescence Technologies and Nanomedicine, University of North Texas Health Science Center, Fort Worth, TX 76107, United States of America. Department of Physics and Astronomy, Texas Christian University, Fort Worth, TX 76129, United States of America
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Topp M, Arnason J, Advani R, Brown J, Allan J, Ansell S, O'Brien S, Chavez J, Duell J, Rosenwald A, Charnas R, Ambati S, Adriaens L, Ufkin M, Zhu M, Li J, Gasparini P, Jankovic V, Fiaschi N, Zhang W, Hamon S, Thurston G, Murphy A, Yancopoulos G, Lowy I, Sternberg D, Bannerji R. CLINICAL ACTIVITY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY (AB) IN PATIENTS (PTS) WITH (W/) RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL). Hematol Oncol 2019. [DOI: 10.1002/hon.58_2629] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M.S. Topp
- Department of Internal Medicine; Universitätsklinikum Würzburg; Würzburg Germany
| | - J. Arnason
- Hematology/Oncology Division; Beth Israel Deaconess Medical Center; Boston United States
| | - R. Advani
- Department of Medicine; Stanford University; Stanford United States
| | - J.R. Brown
- Center for Hematologic Oncology; Dana-Farber Cancer Institute; Boston United States
| | - J. Allan
- Division of Hematology and Medical Oncology; Weill Cornell Medicine; New York United States
| | - S. Ansell
- Department of Internal Medicine; Mayo Clinic; Rochester United States
| | - S. O'Brien
- Division of Hematology/Oncology; University of California; Irvine United States
| | - J. Chavez
- Department of Oncologic Sciences; Moffitt Cancer Center; Tampa United States
| | - J. Duell
- Department of Internal Medicine; Universitätsklinikum Würzburg; Würzburg Germany
| | - A. Rosenwald
- Institute of Pathology; University of Würzburg; Würzburg Germany
| | - R. Charnas
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - S.R. Ambati
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - L. Adriaens
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Basking Ridge United States
| | - M. Ufkin
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - M. Zhu
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - J. Li
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Basking Ridge United States
| | - P. Gasparini
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - V. Jankovic
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - N. Fiaschi
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - W. Zhang
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - S. Hamon
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - G. Thurston
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - A.J. Murphy
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - G.D. Yancopoulos
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - I. Lowy
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - D. Sternberg
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - R. Bannerji
- Section of Hematologic Malignancies; Rutgers Cancer Institute of New Jersey; New Brunswick United States
| |
Collapse
|
10
|
Castillo J, Itchaki G, Paludo J, Varettoni M, Buske C, Eyre T, Chavez J, Shain K, Issa S, Palomba L, Pasvolsky O, Simpson D, Talaulikar D, Tam C, Tedeschi A, Ansell S, Nayak L, Treon S. IBRUTINIB FOR THE TREATMENT OF BING-NEEL SYNDROME: A RETROSPECTIVE, MULTICENTER STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.140_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- J. Castillo
- Bing Center for Waldenstrom Macroglobulinemia; Dana-Farber Cancer Institute; Boston United States
| | - G. Itchaki
- Hematology; Rabin Medical Center; Petah Tikva Israel
| | - J. Paludo
- Hematology and Oncology; Mayo Clinic; Rochester United States
| | - M. Varettoni
- Hematology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - C. Buske
- Comprehensive Cancer Center; University Hospital Ulm; Ulm Germany
| | - T. Eyre
- Hematology; Churchill Hospital; Oxford United Kingdom
| | - J. Chavez
- Malignant Hematology; Moffitt Cancer Institute; Tampa United States
| | - K. Shain
- Malignant Hematology; Moffitt Cancer Institute; Tampa United States
| | - S. Issa
- Hematology; Middlemore Hospital; Auckland New Zealand
| | - L. Palomba
- Hematology and Oncology; Memorial Sloan Kettering Cancer Center; New York United States
| | - O. Pasvolsky
- Hematology; Rabin Medical Center; Petah Tikva Israel
| | - D. Simpson
- Hematology; North Shore Hospital; Auckland New Zealand
| | | | - C. Tam
- Hematology; Peter MacCallum Cancer Centre; Melbourne Australia
| | | | - S. Ansell
- Hematology and Oncology; Mayo Clinic; Rochester United States
| | - L. Nayak
- Center for CNS Lymphoma; Dana-Farber Cancer Institute; Boston United States
| | - S. Treon
- Bing Center for Waldenstrom Macroglobulinemia; Dana-Farber Cancer Institute; Boston United States
| |
Collapse
|
11
|
Ginete-Garcia J, Chavez J, Chico J, Chua E, Danguilan R. ACUTE RESPIRATORY FAILURE WITH PULMONARY HEMORRHAGE DUE TO LEPTOSPIROSIS SUCCESSFULLY MANAGED BY EXTRACORPOREAL MEMBRANE OXYGENATION: THE FIRST IN THE PHILIPPINES. Chest 2019. [DOI: 10.1016/j.chest.2019.02.096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
12
|
Carrillo-Martin I, Kallur L, Cuervo-Pardo L, Chavez J, Mahapatra SS, Mendiola-Jimenez J, Reddy K, Rammoha R, Mohan K, Gonzalez-Estrada A. ‘What is Anaphylaxis’: A Critical Appraisal of the Quality of Anaphylaxis Information on YouTube. J Allergy Clin Immunol 2019. [DOI: 10.1016/j.jaci.2018.12.530] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
13
|
Mahal B, Chavez J, Mahal A, Yang D, Kim D, Sanford N, Sethi R, Hu J, Trinh Q, Nguyen P. Early Impact of the Affordable Care Act and Medicaid Expansion on Racial and Socioeconomic Disparities in Cancer Care. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.1225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
14
|
Juhl P, Domsic R, Bay-Jensen AC, Karsdal M, Siebuhr A, Franchimont N, Chavez J. SAT0200 Serum Biomarkers of Collagen Turnover in Early and Late Diffuse Systemic Sclerosis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
15
|
Siebuhr A, Domsic R, Juhl P, Bay-Jensen AC, Karsdal M, Franchimont N, Chavez J. SAT0214 Macrophage Activation and Biglycan as Disease Activity and Diagnostic Biomarkers in Systemic Sclerosis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
16
|
Chavez J. Psychologists' approaches to understanding abortion and mental health. Contraception 2015. [DOI: 10.1016/j.contraception.2015.06.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
17
|
Natarajan A, Chavez J, Ahn R, Nelson B, Eckardt M, Burke T. Uterine balloon tamponade as a second line treatment for uncontrolled
postpartum hemorrhage: A qualitative study exploring lower level provider
perceptions of effectiveness, feasibility, and acceptability in lower level
health facilities in Kenya. Ann Glob Health 2015. [DOI: 10.1016/j.aogh.2015.02.686] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
18
|
De Benedetti F, Ruperto N, Zuber Z, Cuttica R, Keltsev V, Xavier R, Calvo I, Nikishina I, Rubio N, Alekseeva E, Chasnyk V, Chavez J, Horneff G, Opoka-Winiarska V, Quartier P, Silva C, Silverman E, Spindler A, Keane C, Bharucha K, Wang J, Lovell D, Martini A, Brunner HI. Efficacy and safety of tocilizumab in patients with polyarticular juvenile idiopathic arthritis: 2-year data from the CHERISH study. Rheumatology (Oxford) 2014. [DOI: 10.1093/rheumatology/keu268.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- F. De Benedetti
- IRCCS Ospedale Ped Bambino Gesú, Rome, 2PRINTO, Genova, Italy, 3PRCSG, Cincinnati, OH, USA, 4Roche, Welwyn Garden City, UK and 5Genentech, South San Francisco, CA, USA
| | - N. Ruperto
- IRCCS Ospedale Ped Bambino Gesú, Rome, 2PRINTO, Genova, Italy, 3PRCSG, Cincinnati, OH, USA, 4Roche, Welwyn Garden City, UK and 5Genentech, South San Francisco, CA, USA
| | - Z. Zuber
- IRCCS Ospedale Ped Bambino Gesú, Rome, 2PRINTO, Genova, Italy, 3PRCSG, Cincinnati, OH, USA, 4Roche, Welwyn Garden City, UK and 5Genentech, South San Francisco, CA, USA
| | - R. Cuttica
- IRCCS Ospedale Ped Bambino Gesú, Rome, 2PRINTO, Genova, Italy, 3PRCSG, Cincinnati, OH, USA, 4Roche, Welwyn Garden City, UK and 5Genentech, South San Francisco, CA, USA
| | - V. Keltsev
- IRCCS Ospedale Ped Bambino Gesú, Rome, 2PRINTO, Genova, Italy, 3PRCSG, Cincinnati, OH, USA, 4Roche, Welwyn Garden City, UK and 5Genentech, South San Francisco, CA, USA
| | - R. Xavier
- IRCCS Ospedale Ped Bambino Gesú, Rome, 2PRINTO, Genova, Italy, 3PRCSG, Cincinnati, OH, USA, 4Roche, Welwyn Garden City, UK and 5Genentech, South San Francisco, CA, USA
| | - I. Calvo
- IRCCS Ospedale Ped Bambino Gesú, Rome, 2PRINTO, Genova, Italy, 3PRCSG, Cincinnati, OH, USA, 4Roche, Welwyn Garden City, UK and 5Genentech, South San Francisco, CA, USA
| | - I. Nikishina
- IRCCS Ospedale Ped Bambino Gesú, Rome, 2PRINTO, Genova, Italy, 3PRCSG, Cincinnati, OH, USA, 4Roche, Welwyn Garden City, UK and 5Genentech, South San Francisco, CA, USA
| | - N. Rubio
- IRCCS Ospedale Ped Bambino Gesú, Rome, 2PRINTO, Genova, Italy, 3PRCSG, Cincinnati, OH, USA, 4Roche, Welwyn Garden City, UK and 5Genentech, South San Francisco, CA, USA
| | - E. Alekseeva
- IRCCS Ospedale Ped Bambino Gesú, Rome, 2PRINTO, Genova, Italy, 3PRCSG, Cincinnati, OH, USA, 4Roche, Welwyn Garden City, UK and 5Genentech, South San Francisco, CA, USA
| | - V. Chasnyk
- IRCCS Ospedale Ped Bambino Gesú, Rome, 2PRINTO, Genova, Italy, 3PRCSG, Cincinnati, OH, USA, 4Roche, Welwyn Garden City, UK and 5Genentech, South San Francisco, CA, USA
| | - J. Chavez
- IRCCS Ospedale Ped Bambino Gesú, Rome, 2PRINTO, Genova, Italy, 3PRCSG, Cincinnati, OH, USA, 4Roche, Welwyn Garden City, UK and 5Genentech, South San Francisco, CA, USA
| | - G. Horneff
- IRCCS Ospedale Ped Bambino Gesú, Rome, 2PRINTO, Genova, Italy, 3PRCSG, Cincinnati, OH, USA, 4Roche, Welwyn Garden City, UK and 5Genentech, South San Francisco, CA, USA
| | - V. Opoka-Winiarska
- IRCCS Ospedale Ped Bambino Gesú, Rome, 2PRINTO, Genova, Italy, 3PRCSG, Cincinnati, OH, USA, 4Roche, Welwyn Garden City, UK and 5Genentech, South San Francisco, CA, USA
| | - P. Quartier
- IRCCS Ospedale Ped Bambino Gesú, Rome, 2PRINTO, Genova, Italy, 3PRCSG, Cincinnati, OH, USA, 4Roche, Welwyn Garden City, UK and 5Genentech, South San Francisco, CA, USA
| | - C. Silva
- IRCCS Ospedale Ped Bambino Gesú, Rome, 2PRINTO, Genova, Italy, 3PRCSG, Cincinnati, OH, USA, 4Roche, Welwyn Garden City, UK and 5Genentech, South San Francisco, CA, USA
| | - E. Silverman
- IRCCS Ospedale Ped Bambino Gesú, Rome, 2PRINTO, Genova, Italy, 3PRCSG, Cincinnati, OH, USA, 4Roche, Welwyn Garden City, UK and 5Genentech, South San Francisco, CA, USA
| | - A. Spindler
- IRCCS Ospedale Ped Bambino Gesú, Rome, 2PRINTO, Genova, Italy, 3PRCSG, Cincinnati, OH, USA, 4Roche, Welwyn Garden City, UK and 5Genentech, South San Francisco, CA, USA
| | - C. Keane
- IRCCS Ospedale Ped Bambino Gesú, Rome, 2PRINTO, Genova, Italy, 3PRCSG, Cincinnati, OH, USA, 4Roche, Welwyn Garden City, UK and 5Genentech, South San Francisco, CA, USA
| | - K. Bharucha
- IRCCS Ospedale Ped Bambino Gesú, Rome, 2PRINTO, Genova, Italy, 3PRCSG, Cincinnati, OH, USA, 4Roche, Welwyn Garden City, UK and 5Genentech, South San Francisco, CA, USA
| | - J. Wang
- IRCCS Ospedale Ped Bambino Gesú, Rome, 2PRINTO, Genova, Italy, 3PRCSG, Cincinnati, OH, USA, 4Roche, Welwyn Garden City, UK and 5Genentech, South San Francisco, CA, USA
| | - D. Lovell
- IRCCS Ospedale Ped Bambino Gesú, Rome, 2PRINTO, Genova, Italy, 3PRCSG, Cincinnati, OH, USA, 4Roche, Welwyn Garden City, UK and 5Genentech, South San Francisco, CA, USA
| | - A. Martini
- IRCCS Ospedale Ped Bambino Gesú, Rome, 2PRINTO, Genova, Italy, 3PRCSG, Cincinnati, OH, USA, 4Roche, Welwyn Garden City, UK and 5Genentech, South San Francisco, CA, USA
| | - H. I. Brunner
- IRCCS Ospedale Ped Bambino Gesú, Rome, 2PRINTO, Genova, Italy, 3PRCSG, Cincinnati, OH, USA, 4Roche, Welwyn Garden City, UK and 5Genentech, South San Francisco, CA, USA
| | | |
Collapse
|
19
|
De Benedetti F, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, Cuttica R, Keltsev V, Xavier R, Calvo I, Nikishina I, Rubio-Pérez N, Alekseeva E, Chasnyk V, Chavez J, Horneff G, Opoka-Winiarska V, Quartier P, Silva C, Silverman E, Spindler A, Martini A, Lovell D, Brunner H. OP0060 Efficacy and Safety of Tocilizumab in Patients with Polyarticular Juvenile Idiopathic Arthritis: Data from a Phase 3 Trial. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2013-eular.265] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
20
|
Tobias J, Deere K, Palmer S, Clark E, Clinch J, Fikree A, Aktar R, Wellstead G, Knowles C, Grahame R, Aziz Q, Amaral B, Murphy G, Ioannou Y, Isenberg DA, Tansley SL, Betteridge ZE, Gunawardena H, Shaddick G, Varsani H, Wedderburn L, McHugh N, De Benedetti F, Ruperto N, Espada G, Gerloni V, Flato B, Horneff G, Myones BL, Onel K, Frane J, Kenwright A, Lipman TH, Bharucha KN, Martini A, Lovell DJ, Baildam E, Ruperto N, Brunner H, Zuber Z, Keane C, Harari O, Kenwright A, Cuttica RJ, Keltsev V, Xavier R, Penades IC, Nikishina I, Rubio-Perez N, Alekseeva E, Chasnyk V, Chavez J, Horneff G, Opoka-Winiarska V, Quartier P, Silva CA, Silverman ED, Spindler A, Lovell DJ, Martini A, De Benedetti F, Hendry GJ, Watt GF, Brandon M, Friel L, Turner D, Lorgelly PK, Gardner-Medwin J, Sturrock RD, Woodburn J, Firth J, Waxman R, Law G, Siddle H, Nelson AE, Helliwell P, Otter S, Butters V, Loughrey L, Alcacer-Pitarch B, Tranter J, Davies S, Hryniw R, Lewis S, Baker L, Dures E, Hewlett S, Ambler N, Clarke J, Gooberman-Hill R, Jenkins R, Wilkie R, Bucknall M, Jordan K, McBeth J, Norton S, Walsh D, Kiely P, Williams R, Young A, Harkess JE, McAlarey K, Chesterton L, van der Windt DA, Sim J, Lewis M, Mallen CD, Mason E, Hay E, Clarson LE, Hider SL, Belcher J, Heneghan C, Roddy E, Mallen CD, Gibson J, Whiteford S, Williamson E, Beatty S, Hamilton-Dyer N, Healey EL, Ryan S, McHugh GA, Main CJ, Porcheret M, Nio Ong B, Pushpa-Rajah A, Dziedzic KS, MacRae CS, Shortland A, Lewis J, Morrissey M, Critchley D, Muller S, Mallen CD, Belcher J, Helliwell T, Hider SL, Cole Z, Parsons C, Crozier S, Robinson S, Taylor P, Inskip H, Godfrey K, Dennison E, Harvey NC, Cooper C, Prieto Alhambra D, Lalmohamed A, Abrahamsen B, Arden N, de Boer A, Vestergaard P, de Vries F, Kendal A, Carr A, Prieto-Alhambra D, Judge A, Cooper C, Chapurlat R, Bellamy N, Czerwinski E, Pierre Devogelaer J, March L, Pavelka K, Reginster JY, Kiran A, Judge A, Javaid MK, Arden N, Cooper C, Sundy JS, Baraf HS, Becker M, Treadwell EL, Yood R, Ottery FD. Oral Abstracts 3: Adolescent and Young Adult * O13. Hypermobility is a Risk Factor for Musculoskeletal Pain in Adolescence: Findings From a Prospective Cohort Study. Rheumatology (Oxford) 2013. [DOI: 10.1093/rheumatology/ket200] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Ritesh P, Pahuja S, Chavez J, Braddy W, Skipper M, Bernstein ZP, Chanan-Khan A, Ramanarayanan J, Czuczman MS, Hernandez-Ilizaliturri FJ. Correlation of surface expression of CD11b or CD32 in polymorphonuclear cells (PMNs) and CD69 in natural killer cells (NK) with progression-free survival (PFS) following chemoimmunotherapy with rituximab and liposomal doxorubicin (LD) in patients (pts) with relapsed or refractory B-cell lymphoma. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8583 Antibody dependent cellular citotoxicity (ADCC) play a significant role in rituximab's anti-tumor activity. FcγRIIIa polymorphisms have been associated with clinical responses to rituximab. The predictive value of FcγRIIIa polymorphisms is lost when rituximab is combined with chemotherapy. Alternative assays to assess the immune system had not been studied in patients treated with rituximab plus chemotherapy. To this end, we prospectively studied the pre-treatment quality and function of PMNs and NK cells from pts with refractory/relapsed B-cell lymphomas in a Phase I/II trial. Forty-two B-cell lymphoma patients pts completed treatment. Demographics: 22M:20F; Median age = 61.8 (range 35–83); Patients received R (375 mg/m2/dose) on day 1 and LD (30 mg/m2/dose) on day 3 q21 day × 6 cycles. Pre-treatment flow cytometry was performed to assess surface expression of CD11b, CD62, CD69, CD16, CD32 and CD64 in PMNs or NKcells was performed. Serum or PBMC's were isolated from each patient and used 51Cr release assays to study rituximab-associated complement mediated cytotoxicity (CMC) or ADCC. To correlate laboratory parameters with response rate, and PFS patients were divided in tertiles. Overall, R+LD was very well-tolerated. Overall response rate (ORR) = 68% (39% CR, 19% PR); median time-to-progression (TTP) = 12 m. Surface expression of CD32 in PMNs, and CD69 in NKcells correlated with better response rates. Surface expression of CD11b and CD32 in the PMN's correlated with a longer PFS (P = 0.040 and P = 0.015, respectively).There was a non-statistically significant trend towards an improved in PFS in those patients whom their PBMC's exhibited a higher degree of ex-vivo rituximab ADCC. Our data suggest that R+LD is a safe and effective regimen and that the quality of the immune system prior to a chemo-immunotherapy regimen may play a role in clinical outcomes, specifically the expression of CD11b and CD32 in PMNs or CD69 in NKcells. Our data supports further research in seeking ways to enhance the quality of the immune system to improve responses to rituximab ± chemotherapy. [Table: see text]
Collapse
Affiliation(s)
- P. Ritesh
- RCPI Lymphoma/Myeloma Research Group; Roswell Park Cancer Institute, Buffalo, NY
| | - S. Pahuja
- RCPI Lymphoma/Myeloma Research Group; Roswell Park Cancer Institute, Buffalo, NY
| | - J. Chavez
- RCPI Lymphoma/Myeloma Research Group; Roswell Park Cancer Institute, Buffalo, NY
| | - W. Braddy
- RCPI Lymphoma/Myeloma Research Group; Roswell Park Cancer Institute, Buffalo, NY
| | - M. Skipper
- RCPI Lymphoma/Myeloma Research Group; Roswell Park Cancer Institute, Buffalo, NY
| | - Z. P. Bernstein
- RCPI Lymphoma/Myeloma Research Group; Roswell Park Cancer Institute, Buffalo, NY
| | - A. Chanan-Khan
- RCPI Lymphoma/Myeloma Research Group; Roswell Park Cancer Institute, Buffalo, NY
| | - J. Ramanarayanan
- RCPI Lymphoma/Myeloma Research Group; Roswell Park Cancer Institute, Buffalo, NY
| | - M. S. Czuczman
- RCPI Lymphoma/Myeloma Research Group; Roswell Park Cancer Institute, Buffalo, NY
| | | |
Collapse
|
22
|
|
23
|
Vargas FH, Barlow S, Hart T, Jimenez-Uzcátegui G, Chavez J, Naranjo S, Macdonald DW. Effects of climate variation on the abundance and distribution of flamingos in the Galápagos Islands. J Zool (1987) 2008. [DOI: 10.1111/j.1469-7998.2008.00485.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
24
|
Ruperto N, Lovell DJ, Li T, Quartier P, Chavez J, Huemer C, Kivitz A, Blanco F, Foeldvari I, Hofer M, Sigal L, Block A, Covucci A, Martini A, Giannini EH. Abatacept treatment improves health-related quality of life, pain, and sleep quality in juvenile idiopathic arthritis patients. Pediatr Rheumatol Online J 2008. [PMCID: PMC3334149 DOI: 10.1186/1546-0096-6-s1-p85] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
25
|
Canić S, Tambaca J, Mikelić A, Hartley CJ, Mirković D, Chavez J, Rosenstrauch D. Blood flow through axially symmetric sections of compliant vessels: new effective closed models. Conf Proc IEEE Eng Med Biol Soc 2007; 2004:3696-9. [PMID: 17271096 DOI: 10.1109/iembs.2004.1404038] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Due to a tremendous complexity of the human cardiovascular system it remains unfeasible to numerically simulate larger sections of the circulatory system using the full three-dimensional (viscous, incompressible Navier-Stokes) equations for blood flow in compliant vessels. Several "effective" one-dimensional models have been used to simplify the calculation in the axially symmetric sections. All of the one-dimensional models assume an ad hoc axial velocity profile to obtain a closed system of equations, and the Law of Laplace (the independent ring model) to model the vessel wall behavior. In this work we obtain an effective system of equations with the following two novel features: (1) the effective equations do not require an ad hoc closure assumption (the closure follows from the analysis of the original three-dimensional equations) and (2) the vessel wall is modeled as a nonlinearly elastic shell using the Koiter model or the nonlinear membrane model. The first novelty provides a higher-order accurate solution to the original three-dimensional problem, and the second allows deformations of the vessel wall that are not necessarily small.
Collapse
Affiliation(s)
- S Canić
- Department of Mathematics, University of Houston, Houston, TX 77204, USA
| | | | | | | | | | | | | |
Collapse
|
26
|
Camacho-Zuñiga C, Ruiz-Treviño F, Zolotukhin M, del Castillo L, Guzman J, Chavez J, Torres G, Gileva N, Sedova E. Gas transport properties of new aromatic cardo poly(aryl ether ketone)s. J Memb Sci 2006. [DOI: 10.1016/j.memsci.2006.07.013] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
27
|
Chavez J, Contreras J, Flores J, Chavez A. 14 Primary double tumor as an intrathoratic entity. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)81485-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
28
|
Pal U, Santiago P, Chavez J, Ascencio JA. Structure and growth mechanism study of Wurtzite CdSe nanorods grown by solvothermal techniques. J Nanosci Nanotechnol 2005; 5:609-14. [PMID: 16004127 DOI: 10.1166/jnn.2005.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
Hexagonal cadmium selenide nanorods 32-170 nm in length and 12-28 nm in diameter were grown by a solvothermal technique by reacting cadmium chloride and selenium powders in ethylenediamine at 140 degrees C. Using electron microscopy, the shape, size, and crystal structure of the nanorods were determined. A detailed microscopy analysis revealed that the nanorods grow through the coalescence of very small particles or fiberlike structures of the compound. The size, shape and strain structures in the nanorods are defined by their growth mechanism.
Collapse
Affiliation(s)
- U Pal
- Instituto de Fisica, Universidad Autónoma de Puebla, Apdo. Postal J-48, Puebla, Pue. 72570, Mexico
| | | | | | | |
Collapse
|
29
|
Petrofsky JS, Bweir S, Andal A, Chavez J, Crane A, Saunders J, Laymon M. Joint acceleration during gait in relation to age. Eur J Appl Physiol 2004; 92:254-62. [PMID: 15083367 DOI: 10.1007/s00421-004-1089-2] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/18/2004] [Indexed: 10/26/2022]
Abstract
Forty-four male and female subjects with no history of falling and whose ages ranged from 10 to 68 years participated in a series of experiments to assess movement at the joints during gait while walking in a straight line, in pivot turns and in turns of 0.33 and 0.66 m diameter. Acceleration at the joints in the forward and side-to-side direction was measured by dual-axis accelerometers placed at the ankles, knees, hips, shoulders, and on the head. Eye movement was assessed from electrodes placed on the sides of the eyes. The results of the experiments showed that for people whose age was above 40 years, significant increases in the forward-back and side-to-side movements occurred at all joints and progressively increased with age. By age 60, adverse movement of the joints as much as quadrupled in many subjects when compared to people whose age was 20-30 years. The increase in joint acceleration occurred equally in the front-back and side-to-side planes. The mechanism of the increased joint movement may be due to tendon laxness, peripheral neuropathy or loss of central control of gait due to age. Accelerometry may be a much more sensitive technique to analyze abnormalities in gait than standard video or observational gait analysis. Results are given as mean (SD) unless otherwise stated.
Collapse
Affiliation(s)
- J S Petrofsky
- Department of Physical Therapy, Loma Linda University, Loma Linda, California, USA.
| | | | | | | | | | | | | |
Collapse
|
30
|
Silva LM, Chavez J, Canalli MHB, Zanetti CR. Determination of IgG subclasses and avidity of antithyroid peroxidase antibodies in patients with subclinical hypothyroidism - a comparison with patients with overt hypothyroidism. Horm Res Paediatr 2003; 59:118-24. [PMID: 12637791 DOI: 10.1159/000069069] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/23/2001] [Indexed: 11/19/2022] Open
Abstract
OBJECTIVE To evaluate the immunoglobulin G subclasses of anti-TPO and antibody avidity in patients with subclinical hypothyroidism (sH), overt hypothyroidism (H) and a control group (C). METHODS According to the TSH, fT4 and anti-TPO antibody levels, appraised by immunometric assays, 95 female patients were divided into three groups (sH, H and C). IgG subclass levels and avidity were measured by a homemade ELISA. Results were analyzed by nonparametric tests and Spearman's rank correlation. RESULTS The predominant IgG subclasses detected in both case groups were IgG1 and IgG4 with a significantly higher level of IgG4 in the sH group. Consequently, the IgG1/IgG4 ratio was significantly lower in sH patients. CONCLUSION The higher levels of IgG4 anti-TPO reduced significantly the IgG1/IgG4 ratio in sH patients. These results permit to envisage that increasing this ratio could be useful as a positive predictive factor for the development of overt disease in such patients.
Collapse
Affiliation(s)
- L M Silva
- Department of Internal Medicine - Endocrinology, Vale do Itajaí University, Itajaí Brazil.
| | | | | | | |
Collapse
|
31
|
Sommer B, Vargas MH, Chavez J, Carbajal V, Segura P, Montaño LM. Differences between inhaled and intravenous bronchial challenge to detect O(3)-induced hyperresponsiveness. J Appl Physiol (1985) 2001; 91:2595-601. [PMID: 11717224 DOI: 10.1152/jappl.2001.91.6.2595] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Ozone (O(3))-induced airway hyperresponsiveness in laboratory animals is usually demonstrated through dose-response curves with inhaled or intravenous bronchoconstrictor agonists. However, comparability of these two routes has not been well documented. Thus guinea pig airway responsiveness to ACh and histamine was evaluated 16-18 h after O(3) (3 parts/million, 1 h) or air exposure by two plethysmographic methods (spontaneously breathing and mechanically ventilated) and by two administration routes (inhalatory or intravenous). We found that O(3) caused airway hyperresponsiveness to intravenous, but not to inhaled, agonists, independent of the plethysmographic method used. Suitability of the inhalatory route to detect airway hyperresponsiveness was corroborated with inhaled ACh after an antigen challenge or extending O(3) exposure to 3 h. Acetylcholinesterase activity was not modified after O(3) exposure in lung homogenates and blood samples. Thus inhaled agonists were less effective to reveal the airway hyperresponsiveness after an acute O(3) exposure than intravenous ones, at least for the 1-h exposure to 3 parts/million, and this difference seems not to be related to an O(3)-induced inhibition of the acetylcholinesterase activity.
Collapse
Affiliation(s)
- B Sommer
- Departamento de Investigación en Asma, Instituto Nacional de Enfermedades Respiratorias, Tlalpan 4502, CP 124080, México DF, México
| | | | | | | | | | | |
Collapse
|
32
|
Hirai M, LaFace D, Robinson S, Kelsey L, Johnson R, Wen SF, Warkentin P, Mills K, Vaillancourt M, Chavez J, Leutzinger C, Sumegi J, Neugebauer S, Lehman J, Talmadge C, Maneval D, Talmadge J. Ex vivo purging by adenoviral p53 gene therapy does not affect NOD-SCID repopulating activity of human CD34+ cells. Cancer Gene Ther 2001; 8:936-47. [PMID: 11781656 DOI: 10.1038/sj.cgt.7700390] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2001] [Indexed: 11/09/2022]
Abstract
Co-incubation of a replication-deficient, recombinant adenovirus carrying the wild-type p53 gene (rAd-p53) and hematopoietic stem cell (HSC) products from patients with breast cancer can significantly reduce tumor cell contamination. Whereas this approach provides a powerful tumor cell purging strategy, potential detrimental effects on the HSC population have not been investigated. The ability of human HSC to reconstitute hematopoiesis in severe combined immunodeficient (SCID) mice and to undergo secondary transplantation provides the only nonclinical measure of self-renewing, stem cell function. The objective of this study was to investigate whether co-incubation with rAd-p53 compromised the SCID repopulating activity (SRA) of HSC. Granulocyte colony-stimulating factor-mobilized human CD34+ cells were co-cultured with rAd-p53 at our targeted clinical dose, and the ability of these cells to establish multilineage hematopoiesis in sublethally irradiated, nonobese diabetic (NOD)-SCID mice was investigated. The persistence of human cells in the mice was investigated by flow cytometry, granulocyte-macrophage colony-forming unit assay, and polymerase chain reaction of human Alu sequences. Further, limiting dilution analysis provided a quantitative comparison between the SRA of CD34+ cells co-incubated with rAd-p53 and control CD34+ cells (no rAd-p53 co-incubation). We conclude that co-incubation with rAd-p53 has little effect on the SRA of HSC.
Collapse
Affiliation(s)
- M Hirai
- University of Nebraska Medical Center, Omaha, Nebraska 68198-7660, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Abstract
Flt-3 ligand (FL), a recently described growth factor affecting early hematopoietic progenitor cells, can also support the expansion of dendritic cells secreting IL-12. Since type 2 T cells predominate in asthma and IL-12 prevents the differentiation of naive T lymphocytes to a type 2 phenotype, we hypothesized that FL could prevent the development of asthma-like conditions in the ovalbumin mouse model. We found that co-administration of FL during ovalbumin sensitization abrogated late allergic responses, but had no effect on early allergic responses. Airway hyperresponsiveness to methacholine was also blocked by FL treatment. Analysis of bronchoalveolar lavage (BAL) fluid demonstrated a significant reduction in eosinophils, with concomitant decreases in IL-5 and increases in IFN-gamma levels. However, there was no change in BAL fluid IL-4 and serum IgE levels. These data suggest that FL treatment prevents ovalbumin-induced asthma in the mouse and may provide a useful adjuvant in the treatment of human asthma.
Collapse
Affiliation(s)
- D K Agrawal
- Center for Allergy, Asthma and Immunology, Creighton University School of Medicine, Omaha, NE 68178, USA.
| | | | | | | |
Collapse
|
34
|
Parajuli P, Mosley RL, Pisarev V, Chavez J, Ulrich A, Varney M, Singh RK, Talmadge JE. Flt3 ligand and granulocyte-macrophage colony-stimulating factor preferentially expand and stimulate different dendritic and T-cell subsets. Exp Hematol 2001; 29:1185-93. [PMID: 11602320 DOI: 10.1016/s0301-472x(01)00722-6] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE Mechanisms of T-cell stimulation by Flt3 ligand (Flt3L) and granulocyte-macrophage colony-stimulating factor (GM-CSF) remain unclear. Herein, we compared the effects of Flt3L and GM-CSF on the expansion of dendritic cells (DC) and T-cell subsets and cytokine expression. METHODS Naïve and effector/memory T cells were analyzed by flow cytometry (FC). CD4(+) and CD8(+) T cells and CD11c(+)CD11b(dull/-)(DC1) and CD11c(+)CD11b(+) (DC2) subsets were isolated and the frequency of IFN-gamma-, IL-12- (type 1) and IL-4-, IL-10 (type 2)-producing cells and cytokine mRNA expression evaluated. RESULTS Flt3L expanded both DC1 and DC2 subsets with a significantly higher percentage and number of DC1 than DC2, while GM-CSF preferentially expanded the DC2 subset. Isolated DC1 from Flt3L-injected mice had significantly higher levels of IL-12 (p40) than IL-10, while the converse occurred with DC2. The numbers of naïve and memory T cells were elevated in mice that received Flt3L or GM-CSF. However, the number of memory CD4(+) and CD8(+) T cells was significantly increased in Flt3L as compared to GM-CSF cohorts. While GM-CSF increased the frequency of both type 1 and type 2 cytokine-producing cells, Flt3L significantly augmented the frequency of type 1 T cells. CONCLUSIONS In contrast to GM-CSF, Flt3L preferentially induces the expansion of type 1 T cells. The mechanism of Flt3L-induced T-cell stimulation is associated with the expansion of the IL-12 (p40)-producing DC1 and memory T cells.
Collapse
Affiliation(s)
- P Parajuli
- Wayne State University School of Medicine, Karmanos Cancer Institute, Dept. of Neurologic Surgery, Detroit, Mich., USA
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, Busch MA, Chavez J, Ashley J, Lebo D, McCracken M, Portenoy RK. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001; 91:123-30. [PMID: 11240084 DOI: 10.1016/s0304-3959(00)00427-9] [Citation(s) in RCA: 287] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Oral transmucosal fentanyl citrate (OTFC); Actiq) is a drug delivery formulation used for management of breakthrough cancer pain. Previous studies with open-label comparisons indicated OTFC was more effective than patients' usual opioid for breakthrough pain. The objective of this study was to compare OTFC and morphine sulfate immediate release (MSIR) for management of breakthrough pain in patients receiving a fixed scheduled opioid regimen. This double-blind, double-dummy, randomized, multiple crossover study was conducted at 19 US university- and community-based hospitals and clinics and comprised 134 adult ambulatory cancer patients. Patients were receiving a fixed scheduled opioid regimen equivalent to 60-1000 mg/day oral morphine or 50-300 microg/h transdermal fentanyl, were using a 'successful' MSIR dose (15-60 mg) as defined by entry criteria, and were experiencing 1-4 episodes of breakthrough pain per day. In open-label fashion, OTFC was titrated such that a single unit (200-1600 microg) provided adequate pain relief with acceptable side effects. Successfully titrated patients entered the double-blind phase of the study and received ten prenumbered sets of randomized capsules and oral transmucosal units. Five sets were the successful OTFC dose paired with placebo capsules, and five sets were placebo OTFC paired with capsules containing the successful MSIR dose. Patients took one set of study medication for each episode of target breakthrough pain. Pain intensity (PI), pain relief (PR) and global performance of medication (GP) scores were recorded. Pain intensity differences (PID) were calculated and 15-min PID was the primary efficacy variable. Adverse events were recorded. Sixty-nine percent of patients (93/134) found a successful dose of OTFC. OTFC yielded outcomes (PI, PID, and PR) at all time points that were significantly better than MSIR. GP also favored OTFC and more patients opted to continue with OTFC than MSIR following the study. Somnolence, nausea, constipation, and dizziness were the most common drug-associated side effects. In conclusion, OTFC was more effective than MSIR in treating breakthrough cancer pain.
Collapse
Affiliation(s)
- P H Coluzzi
- The Oncology Center at St. Joseph Medical Plaza, 1140 West LaVeta, Suite 450, Orange, CA 92868, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Abstract
The objective of this study was to determine common practices for testing for Human Immunodeficiency Virus (HIV), particularly in patients with other sexually transmitted diseases (STD) in emergency departments (ED) with residency training in Emergency Medicine. Via mail, 112 directors of academic emergency medicine programs in the United States were surveyed. Surveys from 95 academic institutions were completed, returned, and included in the analysis. Three EDs (3%) routinely tested for HIV in patients with suspected STD. HIV testing was performed in the ED in 54% of responding institutions under special circumstances such as employee testing after occupational exposures (54%), cases of rape (46%), and suspicion of HIV infection by clinical manifestations other than suspected STD (36%). Based on the results it was determined that academic EDs do not routinely test for HIV in patients suspected of having a STD and have variable testing practices and policies regarding other possible HIV exposures.
Collapse
Affiliation(s)
- S R Wilson
- Division of Emergency Medicine, Department of Internal Medicine, University of California, Davis, Sacramento, USA
| | | | | | | |
Collapse
|
37
|
Abstract
OBJECTIVES This study sought to determine the prevalence, characteristics, relation to clinical features and evolution of aortic root disease and valve disease associated with ankylosing spondylitis (AKS). BACKGROUND Aortic root disease and valve disease are common in patients with AKS, but their clinical and prognostic implications have not been well defined. METHODS Forty-four outpatients with AKS and 30 age- and gender-matched healthy volunteers underwent initial transesophageal echocardiography and rheumatologic evaluations. Twenty-five patients underwent clinical and echocardiographic follow-up 39+/-10 months later. RESULTS Aortic root disease and valve disease were common in patients (82%) as compared with controls (27%; p < 0.001). Aortic root thickening, increased stiffness and dilatation were seen in 61%, 61% and 25% of patients, respectively. Valve thickening (41% for the aortic and 34% for the mitral valve) manifested predominantly (74%) as nodularities of the aortic cusps and basal thickening of the anterior mitral leaflet, forming the characteristic subaortic bump. Valve regurgitation was seen in almost half of patients, and 40% had moderate lesions. Except for the duration of AKS, aortic root disease and valve disease were unrelated to the activity, severity or therapy of AKS. During follow-up of 25 patients, in up to 24% new aortic root or valve abnormalities developed, in 12% existing valve regurgitation worsened significantly and in 20% abnormalities resolved. Twenty percent of patients developed heart failure, underwent valve replacement, had a stroke or died, as compared with 3% of control subjects. CONCLUSIONS Aortic root disease and valve disease are common in patients with AKS, are unrelated to clinical features of AKS, can resolve or progress over time and are associated with clinically important cardiovascular morbidity.
Collapse
Affiliation(s)
- C A Roldan
- Division of Cardiology, Veterans Affairs Medical Center, Albuquerque, New Mexico 87108, USA.
| | | | | | | | | |
Collapse
|
38
|
Affiliation(s)
- M G Capulong
- National Kidney and Transplant Institute, East Avenue, Quezon City, Phillipines
| | | | | |
Collapse
|
39
|
Chavez J, Rodriguez M, Romero J. [Current aspects of surgical management of patellar dislocation in the growth period with special reference to Goldthwait surgery]. Z Orthop Ihre Grenzgeb 1998; 136:30-4. [PMID: 9563183 DOI: 10.1055/s-2008-1044647] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
RESEARCH QUESTION The Goldthwait procedure is an operative treatment method for patellar dislocation in children which respects the growth plate. The aim of the study was to analyse the long term results of this procedure. METHODS The results of 36 knees (26 children) operated on because of patellar dislocation according to the Goldthwait technique alone or in combination with other procedures (Krogius, patellar fixation) between 1941-1991 at Balgrist Clinic were analysed. Therefore, we used an own score. RESULTS After a mean follow-up of 16 years (1.5 to 51 years) we found in 77.8% of the cases good and very good subjective results, and in 63.9% good and very good objective results. A recurrence of dislocation occurred in 36.1% of the cases. In 76.9% of these cases a reoperation was performed, of which only one case led to an acceptable final result. The operation results were unsatisfactory in the presence of condylar dysplasia with an angle of more than 160 degrees. The age at the time of surgery and the degree of patellar dysplasia had no effect on the outcome. The success was increased through the use of the Goldthwait procedure in conjunction with other techniques. Pathologic leg axis or severe arthrosis did not occur. CONCLUSION In absence of significant condylar dysplasia the Goldthwait procedure combined with other techniques provides acceptable results. The technique alone is less efficient.
Collapse
Affiliation(s)
- J Chavez
- Orthopädische Universitätsklinik Balgrist, Zürich
| | | | | |
Collapse
|
40
|
Ferguson RP, Kohler FR, Chavez J, Puthumana J, Zaidi S, Shakil H. Discovering asymptomatic biochemical abnormalities on a Baltimore internal medicine service. Md Med J 1996; 45:543-546. [PMID: 8709833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
To assess the frequency of abnormalities that could be discovered through biochemical profile screening on patients admitted to a city hospital internal medicine ward service, we conducted a prospective cross-sectional chart and laboratory review. All unassigned patients admitted to the general medicine service during 1- to 2-month period in late 1993 and the spring of 1994 were eligible. The main outcome measures were frequency of abnormal test results and identification of significance. Admitted patients (N = 222) were evaluated with a 24-panel biochemical profile. Of 5,328 tests, 29% were outside the standard reference range. Of 3,851 tests classified as screening, 1,049 (27%) were outside the reference range. Of overall screening tests, 741 (19%) were judged potentially important by the predetermined criteria. The prevalence did not differ significantly when analyzed by age, race, gender, or history of substance abuse. Our experience indicates that asymptomatic biochemical abnormalities are common in patients admitted to a city hospital medical service and that admission biochemical screening is an effective method of identifying potential comorbidity. Further studies are needed to assess the impact of this approach.
Collapse
Affiliation(s)
- R P Ferguson
- Union Memorial Hospital, Baltimore, Maryland, USA
| | | | | | | | | | | |
Collapse
|
41
|
Abstract
We describe the first reported case of an internal mammary artery originating from the junction of the left subclavian artery and aorta. Noting this, along with other reported anomalies and various pathologic conditions, it appears warranted to perform routine preoperative internal mammary artery angiography before coronary artery bypass surgery.
Collapse
Affiliation(s)
- J Chavez
- Department of Internal Medicine, University of New Mexico School of Medicine and University Hospital, Albuquerque, New Mexico 87131, USA
| | | |
Collapse
|
42
|
Kietzmann M, Markus W, Chavez J, Bollwahn W. [Drug residues in untreated swine]. Dtsch Tierarztl Wochenschr 1995; 102:441-2. [PMID: 8647004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
The concentration of sulfadimidine was measured in the urine of pigs which were housed (over five days) in boxes where other pigs have been treated orally with sulfadimidine before. Sulfadimidine was measured in the urine of the unmedicated pigs in a concentration of up to 4 micrograms/ml. Considering these urine concentrations, violative sulfadimidine tissue residues would be expectable in the carcass after slaughter. The practice of fixing withdrawal times must be considered again to ensure that drug residues in tissues are below the MRL before slaughter also in unmedicated animals.
Collapse
Affiliation(s)
- M Kietzmann
- Institut für Pharmakologie, Pharmazie und Toxikologie, Veterinärmedizinische Fakultät, Universität Leipzig
| | | | | | | |
Collapse
|
43
|
Oreffo RO, Marshall GJ, Kirchen M, Garcia C, Gallwitz WE, Chavez J, Mundy GR, Bonewald LF. Characterization of a cell line derived from a human giant cell tumor that stimulates osteoclastic bone resorption. Clin Orthop Relat Res 1993:229-41. [PMID: 8222432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Giant cell tumors of bone are common but unusual tumors that are comprised of multiple cell types. Most attention has been focused on the giant cells, which resemble osteoclasts morphologically and functionally. This study examines the properties of a cell line derived from mononuclear cells from one of these tumors, since it appears likely that these cells may be able to influence the activities of cells with the osteoclast phenotype. This cell line, C433, has the following characteristics: (1) it represents undifferentiated cells, not recognized by any known antigenic markers for leukocytes; (2) it contains tartrate-resistant acid phosphatase; (3) it responds to the osteotropic factors 1,25 dihydroxyvitamin D3, insulin-like growth factor I and II, but not to parathyroid hormone; (4) it forms sarcomas in nude mice; and (5) it produces an activity that stimulates isolated avian and rat osteoclasts to resorb bone. This cell line may be useful in examining interactions between osteoclasts and accessory cells involved in bone resorption.
Collapse
Affiliation(s)
- R O Oreffo
- University of Texas Health Science Center at San Antonio 78284-7877
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Stockhofe-Zurwieden N, Navarro Camarro JA, Grosse-Beilage E, Chavez J, Pohlenz J. Uterine and placental alterations in pregnant sows associated with the porcine epidemic abortion and respiratory syndrome (PEARS). Zentralbl Veterinarmed B 1993; 40:261-71. [PMID: 8237196 DOI: 10.1111/j.1439-0450.1993.tb00137.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
In the winter of 1990/91 a new, economically devastating disease occurred in european pig breeding herds, characterized by late-term abortion, stillbirth and a high morbidity and mortality of suckling piglets. Because of the clinical picture the disease was named porcine epidemic and respiratory syndrome (PEARS). In this study investigations were carried out in tissues of uterus and placentae of late gestational sows (107 to 112 days of gestation) in three different groups of animals: group I = control animals (n = 2) group II = naturally infected sows (n = 12) from farms, where PEARS recently had been introduced; group III = sows (n = 2), experimentally inoculated with placental homogenates from animals of group II. Both in naturally infected as well as in experimentally infected sows a multifocal, lymphohistiocytic vasculitis and perivascular cell infiltration was observed in the endometrium and maternal part of the placenta, but not in the fetal one. In the fetomaternal unit there were multifocal microseparations of the epithelial layers present. Transmission electron microscopically spherical or oval virus-like particles of 45 to 75 mm in diameter were frequently found on the surface of endothelial cells of blood vessels in the maternal placenta, in a few cases in the intercellular channel system between uterine epithelial cells or on endothelial cells of capillaries in the fetal placenta. Serological results indicate, that an infection with Lelystad virus had occurred in naturally and experimentally infected sows and that transplacental infection was present.
Collapse
|
45
|
Borja R, Chavez J. [Ecuador: private care for those who can pay]. Vardfacket 1991; 15:24-5. [PMID: 1950123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
46
|
Sabatini M, Yates AJ, Garrett IR, Chavez J, Dunn JF, Bonewald L, Mundy GR. Increased production of tumor necrosis factor by normal immune cells in a model of the humoral hypercalcemia of malignancy. J Transl Med 1990; 63:676-82. [PMID: 2232714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
The rat Leydig cell tumor is a well characterized model of the humoral hypercalcemia of malignancy. The studies reported here were provoked by the observation that tumor-bearing rats become extremely cachectic and develop hypertriglyceridemia as they become hypercalcemic. Since the bone resorbing cytokine tumor necrosis factor (TNF)/cachectin is associated with cachexia and hypertriglyceridemia, we examined hypercalcemic tumor-bearing rats for evidence of increased TNF production using a TNF radioimmunoassay. We found that immunoreactive TNF was increased in the plasma of tumor-bearing rats. The increase in plasma TNF was comparable to that previously shown in hypercalcemic nude mice bearing Chinese hamster ovarian cell tumors transfected with the human TNF gene. There was no detectable TNF activity in tumor culture media which suggested that the tumor itself was not the source of excess TNF production. However, we found that tumor cell conditioned media enhanced the production of TNF activity by normal macrophages in vitro, indicating that increased TNF production in vivo may result from a tumor factor(s) which stimulates TNF production by normal immune cells. When TNF was added together with tumor products to organ cultures of fetal rat long bones, osteoclastic bone resorption was potentiated. These data are consistent with the concept that in this model of the humoral hypercalcemia of malignancy, increased TNF production by normal immune cells is increased, has systemic effects as suggested by cachexia and hypertriglyceridemia, and may work in concert with factors produced directly by tumor cells to overwhelm normal calcium homeostasis.
Collapse
Affiliation(s)
- M Sabatini
- University of Texas Health Science Center, Department of Medicine, San Antonio
| | | | | | | | | | | | | |
Collapse
|
47
|
Sabatini M, Chavez J, Mundy GR, Bonewald LF. Stimulation of tumor necrosis factor release from monocytic cells by the A375 human melanoma via granulocyte-macrophage colony-stimulating factor. Cancer Res 1990; 50:2673-8. [PMID: 2183930] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
It has long been known that complex interactions occur between tumors and normal host immune cells. The human melanoma cell line A375 has been used previously as an indicator cell for tumor cell cytotoxicity mediated by monocytes. During other studies on this tumor cell line, we noted that the conditioned media harvested from A375 cultures induced both the human monocytoid cell line U937 and human blood monocytes to release the cytokine tumor necrosis factor (TNF). We characterized this tumor factor which induced TNF release by monocytic cells. Purification was performed using ammonium sulfate precipitation, ion exchange (DEAE) chromatography, gel filtration, and reversed-phase high performance liquid chromatography. The factor copurified with granulocyte-macrophage colony-stimulating factor (GM-CSF). The purified material caused the release of TNF by U937 cells and stimulated formation of granulocyte-macrophage colonies in methyl cellulose. TNF release by U937 cells in response to A375-conditioned medium was inhibited by neutralizing antibodies to GM-CSF. The TNF-inducing activity in A375-conditioned medium was completely removed by an anti-GM-CSF affinity column. Western blotting using antibodies to GM-CSF confirmed a single Mr27,000 band in A375-conditioned medium. We found that recombinant human GM-CSF stimulated TNF production by the same cells as the tumor-conditioned medium. These data show that A375 human melanoma cells produce GM-CSF, which in turn causes TNF production by cells in the monocyte lineage. The combination of GM-CSF production by the tumor and TNF production by immune cells may influence not only tumor growth but also some of the paraneoplastic syndromes associated with malignancy such as hypercalcemia, cachexia and leukocytosis.
Collapse
Affiliation(s)
- M Sabatini
- Department of Medicine, University of Texas Health Science Center, San Antonio 78284-7877
| | | | | | | |
Collapse
|
48
|
Abstract
Three hundred and twenty two clinical isolates of Pseudomonas aeruginosa collected in Morelia, México, were analyzed for in vitro susceptibility to five antibiotics by agar dilution tests. Antibiotic resistance was shown by 50% of total isolates. Frequencies of resistance were: streptomycin, 47%; gentamicin, 13%; tobramycin, 8%; and carbenicillin, 7%; no amikacin resistance was found. The more common resistance patterns were streptomycin, gentamicin-streptomycin, and tobramycin-gentamicin-streptomycin. Resistance to either tobramycin, gentamicin or carbenicillin was found mainly in pyocin type 10 isolates. The proportion of antibiotic resistant isolates ranged from 37 to 75% in four hospitals, and amounted 24% in three clinical laboratories.
Collapse
|
49
|
|
50
|
Ramirez R, Robertstad GW, Hutchinson LR, Chavez J. Mycotic flora in the lower digestive tract of feral pigeons (Columba livia) in the El Paso, Texas area. J Wildl Dis 1976; 12:83-5. [PMID: 1255918 DOI: 10.7589/0090-3558-12.1.83] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Fourteen species of fungus were isolated from the lower digestive tract of 39 of 80 pigeons. Sixteen pigeons had concurrent isolations while two harbored three species. Fungi isolated were Allescheria boydii, Aspergillus spp., Candida krusei, Chrysosporium spp., Geotrichum candidum, Mucor spp., Paeciliomyces spp., Penicillium spp., Rhizopus spp., Rhodotorula spp., Scopulariopsis spp., Streptomyces spp., and Trichosporon cutaneum. There was no apparent evidence that these fungi were associated with clinical disease in any of the pigeons.
Collapse
|